About
Built for the companies traditional CDMOs were not designed to serve.
LucasPye Bio is the CDMO built for innovative therapies — founded in Philadelphia by Dr. Tia Lyles-Williams to drive the full drug development program for seed-stage biotech, so founders can build the company.
One team. One partner. The full picture.
Traditional drug development fragments your program across CDMOs, CROs and regulatory consultants. No one owns the full picture. Data gets lost, handoffs stretch into months, and your runway burns.
LPB was built the other way. We own the program end to end — discovery, preclinical, IND-enabling, CMC, regulatory and clinical — under one integrated network with consistent data standards and real-time e-documentation.
We have one customer: the biotech start-up trying to get a real therapy to patients in 6 to 7 years instead of 12 to 15. That focus shapes everything — how we price, who we partner with, and how we hire.
Founder-led
Founded and led by Dr. Tia Lyles-Williams, with a growing advisory and capital network.
Philadelphia-based
Operational base in Philadelphia, with a partner network active across the U.S. and EU.
Network-powered
Divine Myelin, Celleqore, Higgs Insights and CR Clinical extend our reach without diluting accountability.
Traction
Operational and building momentum.
Partner network
- Divine Myelin — preclinical R&D
- Celleqore — GxP bioanalytical, QA and regulatory
- Higgs Insights — fundraising and investor intros
- CR Clinical — 1,000+ global trial sites
Platform capabilities
- BSL-2 gene and viral vector capacity
- Single-use manufacturing infrastructure
- Digital e-documentation workflows live
- Integrated CMC and eClinical platform
Early engagement
- Active pipeline of seed-stage biotechs
- Philadelphia-based operational base
- Founder-led: Dr. Tia Lyles-Williams
- Growing advisory and capital network
Additional traction details including pipeline, LOIs and IP available upon request.